Abstract
It is suggested that medication for attention-deficit hyperactivity disorder (ADHD) links to lower risk of traumatic brain injury (TBI). Little is known about whether the beneficial effect of methylphenidate is persistent in individuals with other comorbid mental disorders and epilepsy. We identified 90,634 participants who were less than 18 years old and diagnosed with ADHD from Taiwan’s National Health Insurance Research Database (NHIRD) from January 1, 2000 to December 31, 2013. Cox proportional hazards models with hazard ratio (HR) and 95% confidence interval were conducted to compare the risks of TBI event between groups of ADHD-only and ADHD with co-occurring other mental disorders. Within-individual comparisons using a self-controlled case series study design were conducted using conditional Poisson regression models with relative incidence (RR) and 95% CI to examine the effect of methylphenidate on TBI with adjustment for medication of psychotropics and anticonvulsants. For children and adolescents with ADHD, we found comorbid mental disorders and epilepsy increase the risk of TBI, with HRs ranged from 1.21 to 1.75. For the effect of MPH, we found reduced risks for TBI in ADHD (RR = 0.83, 95% CI = 0.70–0.98). Similar results were found among individuals with co-occurring oppositional defiant disorders or conduct disorder, MDD, tic disorders and epilepsy. Methylphenidate treatment was linked to lower risk for TBI in patients with ADHD and the inverse association was persistent among those with other comorbid mental disorders and epilepsy.
Similar content being viewed by others
Availability of data and material
These data were owned by the Taiwan Ministry of Health and Welfare. If researchers are interested in applying the data from Taiwan Ministry of Health and Welfare, information is available at www.mohw.gov.tw.
References
Thomas R, Sanders S, Doust J, Beller E, Glasziou P (2015) Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 135(4):e994-1001. https://doi.org/10.1542/peds.2014-3482
Erskine HE, Norman RE, Ferrari AJ, Chan GC, Copeland WE, Whiteford HA, Scott JG (2016) Long-term outcomes of attention-deficit/hyperactivity disorder and conduct disorder: a systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatr 55(10):841–850. https://doi.org/10.1016/j.jaac.2016.06.016
Chang Z, Lichtenstein P, D’Onofrio BM, Sjolander A, Larsson H (2014) Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatr 71(3):319–325. https://doi.org/10.1001/jamapsychiatry.2013.4174
Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H (2019) Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatr 86(5):335–343. https://doi.org/10.1016/j.biopsych.2019.04.009
Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, Magallon S, Alvarez Zallo N, Luis EO, de Castro-Manglano P, Soutullo C, Arrondo G (2018) Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: a systematic review and meta-analysis. Neurosci Biobehav Rev 84:63–71. https://doi.org/10.1016/j.neubiorev.2017.11.007
Chen VC, Chan HL, Wu SI, Lee M, Lu ML, Liang HY, Dewey ME, Stewart R, Lee CT (2019) Attention-deficit/hyperactivity disorder and mortality risk in Taiwan. JAMA Netw Open 2(8):e198714. https://doi.org/10.1001/jamanetworkopen.2019.8714
Cairney J (2014) Deficits in attention, motor control, and perception and increased risk of injury in children. Dev Med Child Neurol 56(11):1040–1041. https://doi.org/10.1111/dmcn.12509
Rowe R, Maughan B, Goodman R (2004) Childhood psychiatric disorder and unintentional injury: findings from a national cohort study. J Pediatr Psychol 29(2):119–130. https://doi.org/10.1093/jpepsy/jsh015
Tai YM, Gau SS, Gau CS (2013) Injury-proneness of youth with attention-deficit hyperactivity disorder: a national clinical data analysis in Taiwan. Res Dev Disabil 34(3):1100–1108. https://doi.org/10.1016/j.ridd.2012.11.027
Wolraich ML, Hagan JF Jr., Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W, Subcommittee On C, Adolescents With Attention-Deficit/Hyperactive D (2019) Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 144 (4). doi:https://doi.org/10.1542/peds.2019-2528
Pliszka S, Issues AWGoQ (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatr 46(7):894–921. https://doi.org/10.1097/chi.0b013e318054e724
Vaughan B, Kratochvil CJ (2012) Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 21(4):941–955. https://doi.org/10.1016/j.chc.2012.07.005
Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad O, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegard A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Sturmer T, Su CC, Zoega H, Sturkenbroom M, Chan EW, Coghill D, Ip P, Wong ICK (2018) Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatr 5(10):824–835. https://doi.org/10.1016/S2215-0366(18)30293-1
Chen VC, Yang YH, Liao YT, Kuo TY, Liang HY, Huang KY, Huang YC, Lee Y, McIntyre RS, Lin TC (2017) The association between methylphenidate treatment and the risk for fracture among young ADHD patients: a nationwide population-based study in Taiwan. PLoS ONE 12(3):e0173762. https://doi.org/10.1371/journal.pone.0173762
Chang Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, D’Onofrio BM (2017) Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. JAMA Psychiatry 74(6):597–603. https://doi.org/10.1001/jamapsychiatry.2017.0659
Man KKC, Ip P, Chan EW, Law SL, Leung MTY, Ma EXY, Quek WT, Wong ICK (2017) Effectiveness of pharmacological treatment for attention-deficit/hyperactivity disorder on physical injuries: a systematic review and meta-analysis of observational studies. CNS Drugs 31(12):1043–1055. https://doi.org/10.1007/s40263-017-0485-1
Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, Agrawal A, Adeleye AO, Shrime MG, Rubiano AM, Rosenfeld JV, Park KB (2018) Estimating the global incidence of traumatic brain injury. J Neurosurg pp. 1–18. doi:https://doi.org/10.3171/2017.10.JNS17352
Chang HK, Hsu JW, Wu JC, Huang KL, Chang HC, Bai YM, Chen TJ, Chen MH (2018) Traumatic brain injury in early childhood and risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: a nationwide longitudinal study. J Clin Psychiatr 79 (6). doi:https://doi.org/10.4088/JCP.17m11857
Narad ME, Kennelly M, Zhang N, Wade SL, Yeates KO, Taylor HG, Epstein JN, Kurowski BG (2018) Secondary attention-deficit/hyperactivity disorder in children and adolescents 5 to 10 years after traumatic brain injury. JAMA Pediatr 172(5):437–443. https://doi.org/10.1001/jamapediatrics.2017.5746
Liou YJ, Wei HT, Chen MH, Hsu JW, Huang KL, Bai YM, Su TP, Li CT, Yang AC, Tsai SJ, Lin WC, Chen TJ (2018) Risk of traumatic brain injury among children, adolescents, and young adults with attention-deficit hyperactivity disorder in Taiwan. J Adolesc Health 63(2):233–238. https://doi.org/10.1016/j.jadohealth.2018.02.012
Ghirardi L, Larsson H, Chang Z, Chen Q, Quinn PD, Hur K, Gibbons RD, D’Onofrio BM (2019) Attention-deficit/hyperactivity disorder medication and unintentional injuries in children and adolescents. J Am Acad Child Adolesc Psychiatr. https://doi.org/10.1016/j.jaac.2019.06.010
Liao YT, Yang YH, Kuo TY, Liang HY, Huang KY, Wang TN, Lee Y, McIntyre RS, Chen VC (2018) Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan. Eur Child Adolesc Psychiatr 27(3):279–288. https://doi.org/10.1007/s00787-017-1042-7
Brikell I, Chen Q, Kuja-Halkola R, D’Onofrio BM, Wiggs KK, Lichtenstein P, Almqvist C, Quinn PD, Chang Z, Larsson H (2019) Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. Epilepsia 60(2):284–293. https://doi.org/10.1111/epi.14640
Cohen R, Senecky Y, Shuper A, Inbar D, Chodick G, Shalev V, Raz R (2013) Prevalence of epilepsy and attention-deficit hyperactivity (ADHD) disorder: a population-based study. J Child Neurol 28(1):120–123. https://doi.org/10.1177/0883073812440327
Ravi M, Ickowicz A (2016) Epilepsy, attention-deficit/hyperactivity disorder and methylphenidate: Critical examination of guiding evidence. J Can Acad Child Adolesc Psychiatr 25(1):50–58
Jory C, Oak K, Organ C, McLean B, Shankar R (2019) Head first: review of epilepsy head injury risk and protection. Seizure 71:66–79. https://doi.org/10.1016/j.seizure.2019.06.013
Sun S, Kuja-Halkola R, Faraone SV, D’Onofrio BM, Dalsgaard S, Chang Z, Larsson H (2019) Association of psychiatric comorbidity with the risk of premature death among children and adults with attention-deficit/hyperactivity disorder. JAMA Psychiatr 76(11):1141–1149. https://doi.org/10.1001/jamapsychiatry.2019.1944
Ghirardi L, Chen Q, Chang Z, Kuja-Halkola R, Skoglund C, Quinn PD, D’Onofrio BM, Larsson H (2020) Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders. J Child Psychol Psychiatr 61(2):140–147. https://doi.org/10.1111/jcpp.13136
Ng CH (1997) The stigma of mental illness in Asian cultures. Aust N Z J Psychiatr 31(3):382–390. https://doi.org/10.3109/00048679709073848
Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, Lai EC (2019) Taiwan’s National Health Insurance Research Database: past and future. Clin Epidemiol 11:349–358. https://doi.org/10.2147/CLEP.S196293
Lee M-J, Yang K-C, Shyu Y-C, Yuan S-S, Yang C-J, Lee S-Y, Lee T-L, Wang L-J (2016) Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population-based study in Taiwan. J Affect Disord 189:110–117. https://doi.org/10.1016/j.jad.2015.09.015
Chen Q, Sjolander A, Runeson B, D’Onofrio BM, Lichtenstein P, Larsson H (2014) Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 348:g3769. https://doi.org/10.1136/bmj.g3769
Chang Z, D’Onofrio BM, Quinn PD, Lichtenstein P, Larsson H (2016) Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatr 80(12):916–922. https://doi.org/10.1016/j.biopsych.2016.02.018
Kutlu A, Akyol Ardic U, Ercan ES (2017) Effect of methylphenidate on emotional dysregulation in children with attention-deficit/hyperactivity disorder + oppositional defiant disorder/conduct disorder. J Clin Psychopharmacol 37(2):220–225. https://doi.org/10.1097/JCP.0000000000000668
Golubchik P, Rapaport M, Weizman A (2017) The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. Int Clin Psychopharmacol 32(5):289–293. https://doi.org/10.1097/YIC.0000000000000175
Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL (1997) Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatr 36(5):589–596. https://doi.org/10.1097/00004583-199705000-00008
Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA (1982) Stimulant medications precipitate Tourette’s syndrome. JAMA 247(12):1729–1731
Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, Bloch MH (2015) Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatr 54(9):728–736. https://doi.org/10.1016/j.jaac.2015.06.011
Savitz DA, Barón AE (1989) Estimating and correcting for confounder misclassification. Am J Epidemiol 129(5):1062–1071
Acknowledgements
The authors would also like to thank the Health Information and Epidemiology Laboratory (CLRPG6G0043) for their comments and assistance in data analysis.
Funding
This work was supported by grants from the Chang Gung Memorial Hospital (CLRPG6G0042, CLRPG6G0043).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Author Vincent Chin-Hung Chen has been an investigator in a clinical trial from Orient Pharma. The other report no competing interests related to this work.
Ethical statement
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Chen, V.CH., Yang, YH., Lee, C.TC. et al. Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study. Eur Child Adolesc Psychiatry 31, 361–368 (2022). https://doi.org/10.1007/s00787-020-01694-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00787-020-01694-2